Precigen, Inc.
PGENInsider Trading
View AllPrecigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.92M | $6.22M | $26.91M | $14.27M | $31.99M | $31.99M | $160.57M | $230.98M |
| Cost of Revenue | $4.27M | $6.12M | $6.34M | $53.68M | $44.80M | $5.37M | $63.29M | $62.79M |
| Gross Profit | $-342.00K | $106.00K | $20.57M | $-39.41M | $-12.81M | $26.62M | $97.29M | $168.19M |
| Gross Margin | -8.71% | 1.70% | 76.44% | -276.24% | -40.04% | 83.20% | 60.59% | 72.82% |
| Operating Expenses | $134.69M | $99.86M | $96.30M | $52.54M | $73.51M | $112.94M | $602.90M | $306.08M |
| Operating Income | $-135.03M | $-99.76M | $-75.73M | $-91.95M | $-86.32M | $-86.32M | $-505.61M | $-137.89M |
| Operating Margin | -3440.23% | -1602.54% | -281.42% | -644.48% | -269.81% | -269.81% | -314.88% | -59.70% |
| Net Income | $-126.23M | $-95.90M | $28.32M | $-92.17M | $-170.52M | $-170.52M | $-509.34M | $-117.02M |
| Net Margin | -3216.18% | -1540.63% | 105.23% | -646.01% | -533.01% | -533.01% | -317.20% | -50.66% |
| EPS (Basic) | $-0.47 | $-0.39 | $-0.33 | $-0.47 | $-1.02 | $-1.35 | $-3.93 | $-0.98 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |